Akebia Therapeutics, Inc. is facing a potential delisting from the Nasdaq Stock Market after receiving a deficiency letter regarding its stock price. The letter, received on October 21, 2026, indicates that Akebia's common stock has traded below the minimum bid price of $1.00 for the last 30 consecutive business days. This situation is significant for the company as it navigates compliance with Nasdaq's listing standards.
Founded in Delaware, Akebia Therapeutics operates within the pharmaceutical preparations sector, focusing on developing therapies for kidney disease. The company trades under the ticker symbol AKBA on the Nasdaq exchange. This recent filing is part of a series of disclosures that reflect ongoing challenges faced by the company, including its financial performance and stock market standing.
The filing states, "On October 21, 2026, Akebia Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that... the bid price for the Company’s common stock... had closed below $1.00 per share." The notice does not immediately affect the listing of Akebia's common stock.
To regain compliance with Nasdaq's Bid Price Requirement, Akebia has an initial compliance period of 180 calendar days, ending on April 19, 2027. During this time, the company must ensure that its stock price remains at or above $1.00 for at least ten consecutive business days. If it fails to do so, Akebia may be eligible for an additional compliance period, provided it meets other listing requirements.
This situation may affect various stakeholders, including investors, employees, and patients relying on Akebia's products. Investors may face uncertainty regarding the company's future in the stock market, while employees might experience job security concerns. Patients could also be impacted if the company struggles to maintain its operations and product development.
Looking ahead, Akebia intends to monitor its stock price closely and evaluate options to regain compliance, which may include implementing a reverse stock split. However, the filing does not specify what actions will be taken next if compliance is not achieved.